- Home
- INSM vs ITCI Comparison
INSM vs ITCI Comparison
Compare INSM & ITCI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INSM
- ITCI
- Stock Information
- Founded
- INSM 1988
- ITCI 2002
- Country
- INSM United States
- ITCI United States
- Employees
- INSM N/A
- ITCI N/A
- Industry
- INSM Biotechnology: Pharmaceutical Preparations
- ITCI Biotechnology: Pharmaceutical Preparations
- Sector
- INSM Health Care
- ITCI Health Care
- Exchange
- INSM Nasdaq
- ITCI Nasdaq
- Market Cap
- INSM 14.3B
- ITCI 13.5B
- IPO Year
- INSM 2000
- ITCI N/A
- Fundamental
- Price
- INSM $81.06
- ITCI $128.60
- Analyst Decision
- INSM Strong Buy
- ITCI Buy
- Analyst Count
- INSM 15
- ITCI 13
- Target Price
- INSM $92.00
- ITCI $103.92
- AVG Volume (30 Days)
- INSM 1.8M
- ITCI 2.2M
- Earning Date
- INSM 02-20-2025
- ITCI 02-21-2025
- Dividend Yield
- INSM N/A
- ITCI N/A
- EPS Growth
- INSM N/A
- ITCI N/A
- EPS
- INSM N/A
- ITCI N/A
- Revenue
- INSM $363,707,000.00
- ITCI $680,852,000.00
- Revenue This Year
- INSM $20.03
- ITCI $48.28
- Revenue Next Year
- INSM $41.61
- ITCI $37.34
- P/E Ratio
- INSM N/A
- ITCI N/A
- Revenue Growth
- INSM 19.17
- ITCI 46.62
- 52 Week Low
- INSM $21.92
- ITCI $63.30
- 52 Week High
- INSM $84.87
- ITCI $128.77
- Technical
- Relative Strength Index (RSI)
- INSM 58.18
- ITCI 83.90
- Support Level
- INSM $79.50
- ITCI $126.88
- Resistance Level
- INSM $80.28
- ITCI $128.19
- Average True Range (ATR)
- INSM 2.98
- ITCI 0.41
- MACD
- INSM 0.06
- ITCI -1.30
- Stochastic Oscillator
- INSM 63.38
- ITCI 91.01
About INSM Insmed Incorporated
Insmed Inc is a global biopharmaceutical company transforming the lives of patients with serious and rare diseases. The company's first commercial product is ARIKAYCE (amikacin liposome inhalation suspension), approved in the US for the treatment of Mycobacterium Avium Complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. The company's earlier-stage clinical pipeline includes Brensocatib, a novel oral reversible inhibitor of dipeptidyl peptidase 1 with therapeutic potential in non-cystic fibrosis bronchiectasis and other inflammatory diseases; and INS1009, an inhaled formulation of a treprostinil prodrug that may offer a differentiated product profile for pulmonary arterial hypertension.
About ITCI Intra-Cellular Therapies Inc.
Intra-Cellular Therapies Inc is a biopharmaceutical company that develops novel drugs for treating diseases of the central nervous system. The company is focused on the delivery and clinical development of small-molecule drugs that address needs in neuropsychiatric and neurological disorders. Intra-Cellular maintains proprietary chemistry platforms to develop drugs for neurodegenerative diseases. The company's business segment is discovering and developing drugs for the treatment of neurological and psychiatric disorders.